ALAlphabet Inc.

Institutional investor · Portfolio as of Q2 2025

Top Holdings36 positions

Checking export access…
Activity:

AST SPACEMOBILE INC COM CL A

8.9M$417.9M19.6%$24.06+105.15%
2 qtrssince 2025-Q1
Unchanged
0
ARMARM
ADR

Arm Holdings PLC

2M$317.1M14.9%$53.52+209.16%
8 qtrssince 2023-Q3
Unchanged
0

FRESHWORKS INC CLASS A COM

16.2M$241.6M11.3%$15.72-5.74%
11 qtrssince 2022-Q4
Unchanged
0

PLANET LABS PBC COM CL A

31.9M$194.9M9.1%$4.35+39.54%
11 qtrssince 2022-Q4
Unchanged
0

REVOLUTION MEDICINES INC COM

4.1M$152.1M7.1%$28.69+28.65%
7 qtrssince 2023-Q4
Unchanged
0
MTSRMTSRDelisted

METSERA INC

5M$141.2M6.6%——
2 qtrssince 2025-Q1
Unchanged
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

12.2M$136.7M6.4%——
11 qtrssince 2022-Q4
Decreased
0

GITLAB INC CLASS A COM

2.7M$122.9M5.8%$54.31-16.88%
11 qtrssince 2022-Q4
Unchanged
0

TEMPUS AI INC CL A

1.6M$98.6M4.6%$35.00+90.06%
5 qtrssince 2024-Q2
Unchanged
0

DEXCOM INC

1M$90.5M4.2%$122.16-29.33%
11 qtrssince 2022-Q4
Unchanged
0

UIPATH INC CL A

7M$90M4.2%$12.71+0.16%
11 qtrssince 2022-Q4
Unchanged
0

PRIME MEDICINE INC

15.1M$37.2M1.7%$16.12-84.99%
11 qtrssince 2022-Q4
Unchanged
0

MAZE THERAPEUTICS INC COM

2.4M$29.6M1.4%$11.42+6.22%
2 qtrssince 2025-Q1
Unchanged
0

OSCAR HEALTH INC CL A

481,988$10.3M0.5%$2.46+729.67%
11 qtrssince 2022-Q4
Unchanged
0

SANA BIOTECHNOLOGY INC COM

2.8M$7.7M0.4%$3.95-28.86%
11 qtrssince 2022-Q4
Unchanged
0

MONTE ROSA THERAPEUTICS INC COM

1.5M$6.6M0.3%$7.61-39.55%
11 qtrssince 2022-Q4
Unchanged
0

VERA THERAPEUTICS INC CL A

241,264$5.7M0.3%$19.35+21.76%
11 qtrssince 2022-Q4
Unchanged
0

BEAM THERAPEUTICS INC COM

321,604$5.5M0.3%$39.11-57.04%
11 qtrssince 2022-Q4
Unchanged
0

Relay Therapeutics Inc

1.6M$5.4M0.3%$14.94-77.91%
11 qtrssince 2022-Q4
Unchanged
0

DIANTHUS THERAPEUTICS INC COM

208,697$3.9M0.2%$13.67+28.97%
8 qtrssince 2023-Q3
Unchanged
0
$2.1B
AUM
36
Positions
Q2 2025
Filing
HI score · 2.5/5
Quarterly 13F Value Change
+17%Q1'24$2.5B-21%Q2'24$2B-7%Q3'24$1.8B-7%Q4'24$1.7B-8%Q1'25$1.6B+35%Q2'25$2.1B
Activity profile
$ moved · Q2'25
New2%Increased0%Decreased67%Exited31%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.0 years
<1Q3%1-4Q11%1-2Y14%2Y+72%

Alphabet Inc. manages $2.1B across 36 positions as of Q2 2025. Top holdings: ASTS (19.6%), ARM (14.9%), FRSH (11.3%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q2 2025 Summary

Added 1 new position, exited 5, trimmed 1. No standout high-conviction moves this quarter. Portfolio: $2.1B across 36 positions.

Top holdings by portfolio weight

Total AUM$2B
ASTS19.57%
ARM14.85%
FRSH11.32%
PL9.13%
RVMD7.12%
MTSR6.61%
VERV6.40%
GTLB5.76%
TEM4.62%
DXCM4.24%
Other4.22%

Portfolio allocation by GICS sector

Sectors4
Technology55.72%
Healthcare28.76%
Industrials9.13%
Unknown6.40%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L56
Conviction35
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used